# Benefit of Changing Chemoradiotherapy Sequence and Modifying Radiotherapy Schedule for Advanced Nasopharyngeal Cancer

> **NCT00577057** · NA · UNKNOWN · sponsor: **Hospital Authority, Hong Kong** · enrollment: 798 (estimated)

## Conditions studied

- Nasopharyngeal Neoplasms

## Interventions

- **PROCEDURE:** Conventional Radiotherapy
- **PROCEDURE:** Accelerated Radiotherapy
- **DRUG:** Cisplatin
- **DRUG:** 5-fluorouracil
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT00577057
- **Lead sponsor:** Hospital Authority, Hong Kong
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-09
- **Primary completion:** —
- **Final completion:** 2013-08
- **Target enrollment:** 798 (ESTIMATED)
- **Last updated:** 2013-08-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00577057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00577057, "Benefit of Changing Chemoradiotherapy Sequence and Modifying Radiotherapy Schedule for Advanced Nasopharyngeal Cancer". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00577057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*